5th ADC Analytical Development Summit

Optimizing ADC Physiochemical, Potency, and Impurity Analytical Methods to Enhance Product Understanding, Quality and Assess DARs for Regulatory Submissions

The 5th ADC Analytical Development Summit is the only dedicated platform for tackling the unique analytical complexities of ADC development, bringing together technical leaders to ensure a high-quality, regulatory-compliant ADC product.

The ADC landscape is undergoing a rapid transformation with novel modalities like bispecifics, dual payload conjugates, and novel conjugates all push the boundaries of innovation, whilst more traditional ADCs are progressing their way through the pipelines - analytical teams are facing greater challenges in ensuring product quality and regulatory compliance than ever. The 5th ADC Analytical Development Summit is your essential, technical, forum to unite with your analytical development peers and senior decision makers to deep dive and combat challenges spanning early-stage to later-stage analytical development and take away actionable insights for your ADC programs.

URLs:
Website: https://go.evvnt.com/3421742-2?pid=2874
Brochure: https://go.evvnt.com/3421742-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Conference + Workshop Day - Drug Developer: USD 4397.00,
Conference Only - Drug Developer: USD 3099.00,
Conference + Workshop Day - Academic Pricing: USD 3797.00,
Conference Only - Academic Pricing: USD 2699.00,
Conference + Workshop Day - Service Provider: USD 5297.00,
Conference Only - Service Provider: USD 3799.00

Speakers: Alexander Lee, Senior Scientist, Abbvie, Mariele Wolke, Scientist, Abbvie, Esohe Idusogie, Independent CMC Consultant, ADC Therapeutics, Tomohiro Takasugi, Researcher, Astellas Pharma, Xiaoying Ye, Senior Scientist, AstraZeneca, Amanda Ampey, Associate Director, AstraZeneca, Yiyuan Ding, Senior Principal Scientist, Bristol Myers Squibb, Huiyuan Li, Principal Scientist, Bristol Myers Squibb, Bastiaan Duivelshof, Analytical PM, Debiopharm, Edwin Lozano, Associate Scientist Oligonucleotide, Denali Therapeutics Inc., Stacey Cummins-Bitz, Director - Analytical Sciences, Eli Lilly and Co., Michael Liu, Senior Scientist, Biologics Analytical Development, FibroGen, Adrienne Wildt, Associate Director - Chemistry, Manufacturing, and Controls Bioanalytical, ImmunoGen, Wona Joo, Prins Sci, Johnson and Johnson, Zhengqi Zhang, Senior Scientist, Merck and Co, Anita Liu, Associate Principal Scientist, Merck and Co, John Valliere-Douglass, Senior Director - Analytical Sciences, Pfizer, Susan Clardy, Director, Head of Analytical Development and Quality Control, Pyxis Oncology, Melvin Flores, Senior Director - Quality Control Analytical and Microbiology, Sutro Biopharma, Scott Baggett, Principal Scientist - Analytical Chemistry, Sutro Biopharma, Francis Poulin, Head of Analytical Development Biologics Late Stage, Takeda Pharmaceutical